Literature DB >> 30295400

Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Kelly E Dunn1, Elise M Weerts1, Andrew S Huhn1, Jennifer R Schroeder1, David Andrew Tompkins1, George E Bigelow1, Eric C Strain1.   

Abstract

Opioid use disorder (OUD) is a public health crisis. Differences in opioid withdrawal severity that predict treatment outcome could facilitate the process of matching patients to treatments. This is a secondary analysis of a randomized controlled trial (RCT) that enrolled treatment seeking heroin-users (N = 89, males = 78) into a residential study. Participants maintained on morphine (30 mg, subcutaneous, four-times daily) underwent a naloxone (0.4 mg, IM = intramuscular) challenge session to precipitate withdrawal. Area-under-the-curve (AUC) values from self-reported withdrawal ratings during the challenge session were analyzed using K-means clustering, revealing two phenotype groups. Withdrawal and retention from the subsequent 14-day double-blind, double-dummy RCT comparing three study medications (clonidine, tramadol-ER, and buprenorphine) were evaluated as a function of phenotype. Cluster analyses suggested HIGH (N = 37; mean [SD] subjective opiate withdrawal scale [SOWS]-AUC 123.7 [65.8]) and LOW (N = 52; SOWS-AUC 68.0 [47.7]) withdrawal phenotype groups. HIGH participants were significantly more female and had lower body mass indices than LOW participants; no drug-use variables were significant. Regarding RCT outcomes, HIGH phenotype participants were less likely to be retained in the study (P = 0.02) and had higher mean self-reported withdrawal (P = 0.05) than LOW phenotype participants. A significant interaction in RCT retention was observed between phenotype (P = 0.02) and study medication (P < 0.01). Self-reported withdrawal was significant for phenotype (P = 0.02); study medication trended towards significance (P = 0.07). Results suggest patients have meaningfully different experiences of opioid withdrawal that may predict differential response to opioid pharmacotherapies during supervised withdrawal. Additional prospective research to replicate and more thoroughly evaluate withdrawal phenotype correlates and sex differences is warranted.
© 2018 Society for the Study of Addiction.

Entities:  

Keywords:  buprenorphine; opioid; personalized medicine; withdrawal

Year:  2018        PMID: 30295400      PMCID: PMC6546557          DOI: 10.1111/adb.12680

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  40 in total

1.  Developing and validating a human laboratory model to screen medications for smoking cessation.

Authors:  Sherry A McKee; Andrea H Weinberger; Julia Shi; Jeanette Tetrault; Sabrina Coppola
Journal:  Nicotine Tob Res       Date:  2012-04-06       Impact factor: 4.244

Review 2.  Opioid genetics: the key to personalized pain control?

Authors:  R Branford; J Droney; J R Ross
Journal:  Clin Genet       Date:  2012-07-27       Impact factor: 4.438

3.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

Review 4.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

5.  Empirically derived subtypes of opioid use and related behaviors.

Authors:  Grace Chan; Joel Gelernter; David Oslin; Lindsay Farrer; Henry R Kranzler
Journal:  Addiction       Date:  2011-04-28       Impact factor: 6.526

6.  Predicting completion of outpatient opioid detoxification with clonidine.

Authors:  Stephen Strobbe; Kirk J Brower; Luke W Galen
Journal:  Am J Addict       Date:  2003 May-Jun

7.  Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts.

Authors:  T R Kosten; B J Rounsaville; H D Kleber
Journal:  Am J Drug Alcohol Abuse       Date:  1985       Impact factor: 3.829

8.  Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.

Authors:  Oscar A Linares; David Daly; Annemarie Daly Linares; Darko Stefanovski; Raymond C Boston
Journal:  Pain Med       Date:  2014-02-12       Impact factor: 3.750

9.  Hydrocodone in postoperative personalized pain management: pro-drug or drug?

Authors:  M Elaine Stauble; Andrew W Moore; Loralie J Langman; Mark V Boswell; Richard Baumgartner; Suzanne McGee; Jonathan Metry; Saeed A Jortani
Journal:  Clin Chim Acta       Date:  2013-11-21       Impact factor: 3.786

10.  More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic.

Authors:  Peter D Friedmann; Joji Suzuki
Journal:  Addict Sci Clin Pract       Date:  2017-11-15
View more
  12 in total

Review 1.  Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder.

Authors:  Andrew S Huhn; Meredith S Berry; Kelly E Dunn
Journal:  Am J Addict       Date:  2019-05-26

Review 2.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

3.  The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.

Authors:  Cecilia L Bergeria; Andrew S Huhn; D Andrew Tompkins; George E Bigelow; Eric C Strain; Kelly E Dunn
Journal:  Drug Alcohol Depend       Date:  2019-07-16       Impact factor: 4.492

Review 4.  Sex differences in opioid receptor mediated effects: Role of androgens.

Authors:  Jessica L Sharp; Tallia Pearson; Mark A Smith
Journal:  Neurosci Biobehav Rev       Date:  2022-01-04       Impact factor: 8.989

Review 5.  Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.

Authors:  Martha L Velez; Chloe J Jordan; Lauren M Jansson
Journal:  Neurotoxicol Teratol       Date:  2021-08-19       Impact factor: 3.763

6.  The subjective experience of heroin effects among individuals with chronic opioid use: Revisiting reinforcement in an exploratory study.

Authors:  Suky Martinez; Laura Brandt; Sandra D Comer; Frances R Levin; Jermaine D Jones
Journal:  Addict Neurosci       Date:  2022-08-28

Review 7.  Cues conditioned to withdrawal and negative reinforcement: Neglected but key motivational elements driving opioid addiction.

Authors:  Caroline B Pantazis; Luis A Gonzalez; Brendan J Tunstall; Stephanie A Carmack; George F Koob; Leandro F Vendruscolo
Journal:  Sci Adv       Date:  2021-04-07       Impact factor: 14.136

Review 8.  The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.

Authors:  Joao P De Aquino; Suprit Parida; Mehmet Sofuoglu
Journal:  Clin Drug Investig       Date:  2021-04-05       Impact factor: 2.859

9.  Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Authors:  Andrew S Huhn; Patrick H Finan
Journal:  Exp Clin Psychopharmacol       Date:  2021-06-10       Impact factor: 3.157

10.  Complex Interactions Between Sex and Stress on Heroin Seeking.

Authors:  Jordan S Carter; Angela M Kearns; Carmela M Reichel
Journal:  Front Neurosci       Date:  2021-12-10       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.